VanEck Bionic Engineering UCITS ETF                  
Sustainability-related information pursuant to Art. 37 of Regulation (EU) 2022/2088 (“SFDR”) 
 
Product name: VanEck Bionic Engineering UCITS ETF 
 
 
Legal entity identifier: 254900QPAYF1L0Z4C422 
ISIN: IE0005TF96I9 
 
a) Summary  
VanEck Bionic Engineering UCITS ETF (o “Fundo”) foi classificado como Artigo 9(1) do Regulamento (UE) 2019/2088 
sobre divulgações relacionadas à sustentabilidade no setor de serviços financeiros ("SFDR"). O Fundo tem um objetivo 
de investimento sustentável, com ênfase em objetivos sociais: visa contribuir para o desenvolvimento de tecnologias 
biónicas de saúde e, assim, melhorar a qualidade de vida humana. Contribui para objetivos sociais alinhados com os 
Objetivos de Desenvolvimento Sustentável (ODS) “Boa Saúde e Bem-Estar” e “Desigualdade Reduzida”. Com o 
objetivo de atingir o objetivo de investimento sustentável, o Fundo incorpora considerações de sustentabilidade no 
seu processo de investimento passivo por meio da integração de características ESG, exclusão relacionada a ESG e 
votação por procuração em questões de sustentabilidade. 
O Fundo tem uma política de investimento passivo, em que replica o mais próximo possível o seu referencial de 
referência e investe em instrumentos financeiros diretos, 100% sustentáveis. As diretrizes de investimento do fundo 
não exigem um alinhamento especificamente definido com a taxonomia da UE. VanEck Bionic Engineering UCITS ETF 
investe em empresas com pelo menos 50% (25% para componentes atuais) das suas receitas das seguintes linhas de 
negócios: implantes médicos, dentários ou relacionados à visão, bioimpressão, prótese ou preservação de órgãos e 
tecidos. O Índice subjacente não considera empresas envolvidas em dispositivos implantáveis ou vestíveis ou 
materiais usados apenas para fins cosméticos. Além disso, certas exclusões relacionadas a ESG são aplicadas de 
acordo com a metodologia do Índice para garantir que as empresas não prejudiquem significativamente qualquer 
outro objetivo de investimento sustentável ambiental ou social.  
 
Além disso, certas exclusões relacionadas a ESG são aplicadas de acordo com a metodologia do Índice para garantir 
que as empresas não prejudiquem significativamente qualquer outro objetivo de investimento sustentável ambiental 
ou social. As apresentações consideram: 
 
1. Envolvimento controverso do setor em que as empresas são avaliadas quanto ao envolvimento em: 
• 
Armas controversas: um limite de receita de 0% é aplicado; 
• 
Tabaco, carvão térmico, combustíveis fósseis, areias betuminosas, energia nuclear, armas civis, 
militares e jogos de azar: um limite de receita de 5% é aplicado. 
2. As violações de padrões internacionais, por ex. direitos humanos, direitos laborais, risco ambiental e 
suborno.  
 
Por meio das suas políticas de apresentação ESG e votação por procuração, o Fundo considera vários indicadores 
principais adversos, como emissões de efeito de estufa, biodiversidade, água, resíduos, questões sociais e laborais, 
respeito pelos direitos humanos, anticorrupção e antissuborno. 
 
b) No significant harm to the sustainable investment objective 
This Financial product does not significantly harm any other environmental or social sustainable investment objective. 
By means of Norm-based research and Controversial sector involvement screenings, the Fund takes the Principal

adverse impacts on sustainability factors relating to greenhouse gas emissions, biodiversity, water, waste, social and 
employee, respect for human rights, anti-corruption and anti-bribery matters into account. In addition, the Fund 
excludes companies when ISS rating shows the verifiably violated or imminent to violate the OECD Guidelines for 
Multinational Enterprises and the UN Guiding Principles on Business and Human Rights.   
c) Sustainable investment objective of the financial product 
This Fund aims at enhancing and developing products that increase the quality of life by providing goods and services 
vital to preservation, correction and augmentation of  human body functions, thereby contributing to social objectives 
aligned with the SDG goal “Good Health and Well-being”. 
 
Therefore, the Fund aims at investing in companies which were determined by the Index Provider to generate a 
significant (>50%, >25% for current components) part of their revenues from medical implants, prosthesis, or 
bioprinting and preservation of organs and tissues. 
d) Investment strategy 
The Fund’s investment objective is to replicate, before fees and expenses, the price and yield performance of the 
MVIS Global Bionic Healthcare ESG Index. The Fund seeks to invest in companies generating revenues from the 
medical, dental or vision-related implants, bioprinting, prosthesis, or preservation of organs and tissue. This does not 
include companies involved in implantable or wearable devices or materials used only for cosmetic purposes. In 
addition, the ESG-tilted voting policy is applied, whereby casted votes in shareholder meetings of companies in the 
portfolio concern  sustainability matters. 
A third-party engagement specialist - Glass Lewis Europe Limited - for the passive equity funds managed by VanEck 
Asset Management B.V. has been engaged. The engagement provider determines the engagement approach in 
accordance with its engagement policy and based on its engagements´ priorities.  
 
Good governance practices of the investee companies are assessed by excluding companies that very severely violate 
the OECD Guidelines for Multinational Enterprises and and the UN Guiding Principles on Business and Human Rights. 
e) Proportion of investments 
The Fund invests in direct financial instruments of which 100% is sustainable. All of these sustainable investments are 
socially sustainable. 
 
 
 
 
 
f) Monitoring of sustainable investment objective 
The sustainable investment objective is monitored in the following manner: 
Investments
#1 Sustainable
Environmental 
Taxonomy-aligned
Other
Social
#2 Not 
sustainable

The Fund aims at enhancing and developing products that increase the quality of life by providing goods and 
services vital to preservation, correction and augmentation of  human body functions, thereby contributing to social 
objectives aligned with the SDG goal  “Good Health and Well-being” 
1. The sustainable investment objective alignment is measured with the following indicator(s): 
• 
The weighted percentage of investee companies’ revenues derived from medical implants, prosthesis, 
or bioprinting and preservation of organs and tissues. 
• 
The % of portfolio involved in violations of UN Global Compact, the OECD Guidelines for Multinational 
Enterprises and the UN Guiding Principles for Business and Human Rights. The target is 0% at 
rebalancing; 
• 
The % of portfolio involved in the fossil fuels industry, which cannot be higher than 5% at rebalancing; 
• 
The % of portfolio involved in non-renewable energy production. 
2. This is monitored in the following manner: 
• 
The requirements relating to the percentage of companies’ revenues derived from hydrogen projects , 
Norm-based research and Controversial sector involvement screenings (tobacco, fossil fuels, thermal 
coal mining, gambling, oil sands, civilian firearms, military equipment and services, and nuclear power)  
are included in the Index rules which are defined by the Index provider.  
• 
Companies are screened for compliance with the Index rules and the Index is rebalanced on a periodic 
basis by the Index Provider.   
• 
The Fund replicates the Index based on the Index rules.  
• 
Any breaches of the index rules are reported by the Legal and Compliance Team. 
• 
VanEck has policies in place to assess the alignment of the Fund’s investments with the Index and to 
undertake recovery measures where necessary.  
 
The Glass Lewis ESG tilted voting policy is applied, whereby casted votes concern sustainability matters. 
1. This is monitored in the following manner: 
• 
VanEck has appointed a service provider to exercise voting rights.  
• 
VanEck is periodically informed by the service provider on the voting activities.  
 
An engagement approach with some of the underlying companies in accordance with Glass Lewis Europe Limites 
engagement policy and based on its engagements´ priorities.  
1. This is monitored in the following manner: 
• 
VanEck has appointed a service provider to exercise engagement. VanEck is periodically informed by the 
service provider on the engagement activities and has access to the related platform.  
 
g) Methodologies 
The screening of companies consists of a few components as described above. The exact methodology of the Fund’s 
sustainable investments objective is determined by the Index provider. More information can be found in the Fund’s 
index rules.  
Voting is delegated to Glass Lewis. Glass Lewis determines the voting approach based on its assessment of the 
voting proposals and the alignment with the voting policy. VanEck is periodically informed on the activities and has 
access to an online platform where the information on the proxy voting, policy implementation, recordkeeping and 
reporing can be found. 
 
h) Data sources and processing 
The data sources used

1. ISS for global norms, revenue exposure and controversial weapons involvement screenings through the 
index provider 
2. Investee companies’ revenues derived from the bionic implants industry through the index provider. 
3. ISS for data on company involvement in non-renewable energy production. 
4. Glass Lewis data related to voting activities 
 
The measures taken to ensure data quality 
The mentioned data sources are used by VanEck and/or its index provider and service provider. VanEck does not 
receive most of the the data directly from data providers. With regards to the non-renewable energy production data 
VanEck utilizes a reporting service whereby calculations can be made in a tool developed by the data provider. Data 
quality measures are integrated into the reporting service tool. It is alsorelevant that the data used by the index 
provider and service provider is of sufficient quality. The index provider and service provider have set up their internal 
processes to do so. Data quality is a component of the selection process of the index provider.  
 
How data are processed 
VanEck does not process most of the data on its own for the Fund. Other than the reporting service tool VanEck uses, 
the reports it receives on a periodic basis come from the index provider and the service provider. VanEck is periodically 
informed on the index construction, implementation, results and progress of the voting activities.  
 
The proportion of data that are estimated 
VanEck does not estimate data, but cannot rule out that the index provider or service provider does estimate data 
and/or use data provider wich estimate data. Although reported data is preferred, missing information is often 
supplemented with estimated data by the data providers. For more information on how this exactly is determined, 
we refer to the website of the mentioned data providers, index provider and service provider.  
i) Limitations to methodologies and data 
VanEck recognizes the following limitations to methodologies and data: 
1. Lack of reported data 
In order to attain the sustainable investment objective, data from external data providers is used by the index 
provider, VanEck and/or service provider. Data providers retrieve data from company reports (such as annual 
reports). Not all companies report the data. Missing data is sometimes estimated by dataproviders and at times 
there is no data coverage when it is not possible to estimate the data. This means that in not all cases reported data 
is present to determine whether the sustainable investment objective attained. By means of choosing a reputable 
data provider, the risk of erroneous estimates is mitigated. 
2. Actualisation of data 
The index provider rebalances the index on a periodic basis. It is possible that the Fund’s do not fully comply with 
the sustainable investment objective in between the fund rebalancing moments. 
j) Due diligence 
VanEck does not select investments, but uses indices which are constructed by index providers. As described in the 
monitoring section, The Fund replicates the index and this is monitored by the Portfolio Management Team and the 
Legal and Compliance Team.  
 
VanEck has a due diligence process on the selection of index providers and service provides. The board of VanEck 
decides on the selection of an index or service provider. The proposal for an index or service provider is prepared by 
the Portfolio Management Team. VanEck is responsible for monitoring the replication of the index and the service 
provider.

VanEck‘s approach is to achieve and maintain the highest standards of integrity, reporting and internal control on all 
relevant environmental, social, and governance (ESG) matters, sustainability factors in its policies, practices, 
operational set-up and selection and monitoring of investments as well as identification and mitigation of ESG related 
risks. A more detailed description on the due diligence that VanEck carries out is available in the ESG Due Diligence 
Policy, which can be found at the following link: Policies & Procedures | VanEck. 
 
k) Engagement policies 
The financial product engagement is limited to dialogues with the index provider in further refining the index 
rules and can relate to the increasing consideration of sustainability factors in the composition of the index. The 
VanEck Shareholder Engagement Policy can be found here. Furthermore, a third-party engagement specialist - 
Glass Lewis Europe Limited - for the passive equity funds managed by VanEck Asset Management B.V. has been 
engaged. The engagement provider determines the engagement approach in accordance with its engagement 
policy and based on its engagements´ priorities. 
l) Attainment of the sustainable investment objective 
As a passive investments strategy, the Fund has designated its underlying index, the MVIS® Global Bionic Healthcare 
ESG Index, as reference benchmark to meet the sustainable investment objective. 
Sustainability factors are considered as part of screenings which are included in the reference benchmark and 
assessed at any rebalancing of the underlying Index. By means of Norm-based research and Controversial sector 
involvement screenings, the Fund takes sustainability factors relating to greenhouse gas emissions, biodiversity, 
water, waste, social and employee, respect for human rights, anti-corruption and anti-bribery matters into account. 
More information on the reference benchmark can be found here.